Menu

Image of the Day: Bird-of-Paradise

A unique courtship dance clued researchers in to the fact that they had a new species on their hands.

Apr 25, 2018
The Scientist Staff, The Scientist Staff

Cape presentation display of L. superba (A, C, E) and L. niedda (B, D, F)EDWIN SCHOLES, TIM LAMAN

Birds-of-paradise (Aves: Paradisaeidae), a family of passerine birds that includes more than 40 species, have an elaborate courtship display. The male dances frenetically, showing off brightly colored plumage and calling to his mate. Now, researchers have identified a new species in the bird-of-paradise genus Lophorina by analyzing the first-ever audiovisual recordings of its courtship dance. They describe their findings in a study published last week (April 16) in PeerJ

The new species, L. niedda, is the fourth bird-of-paradise species found in the Bird’s Head region of Indonesian New Guinea. Its courtship routine begins with more-intense shaking of its cape—a set of ornamental feathers on its head and upper back—than its close cousin L. superba exhibits. It also includes a more-pronounced cape presentation later in the dance.

E. Scholes, T. Laman, “Distinctive courtship phenotype of the Vogelkop Superb Bird-of-Paradise Lophorina niedda Mayr, 1930 confirms new species status,” PeerJ, doi:10.7717/peerj.4621, 2018.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.